233 results
6-K
EX-99.2
BLRX
Bioline Rx Ltd
28 May 24
BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate
7:11am
and other resources will be sufficient to fund its projected cash requirements into 2025.
The execution of an independent commercialization plan … the outcome of this uncertainty.
Management’s plans include the independent commercialization of the Company’s product, as aforementioned, and, if and when
6-K
EX-99.3
BLRX
Bioline Rx Ltd
28 May 24
BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate
7:11am
executing on an independent commercialization plan in the U.S. for APHEXDA in stem cell mobilization for autologous bone marrow transplantation … controlled by the independent investigator-sponsor and are, therefore, subject to change). Initial data from this study is expected in the second half
6-K
EX-10.1
BLRX
Bioline Rx Ltd
1 Apr 24
BioLineRx Announces $6 Million Registered Direct Offering
10:35am
bid price per ADS so reported, or (d) in all other cases, the fair market value of an ADS as determined by an independent appraiser selected in good … independent registered accounting firm is set forth in the Prospectus. To the knowledge and belief of the Company, such accounting firm (i
6-K
EX-10.2
BLRX
Bioline Rx Ltd
1 Apr 24
BioLineRx Announces $6 Million Registered Direct Offering
10:35am
of the Exercise Price to an independent, reputable investment bank selected by the Company and approved by the Holder or (b) the disputed arithmetic calculation … of the Warrant ADSs to the Company’s independent, outside accountant. The Company shall cause at its expense the investment bank or the accountant
6-K
EX-5.2
BLRX
Bioline Rx Ltd
1 Apr 24
BioLineRx Announces $6 Million Registered Direct Offering
10:35am
, fully paid and non-assessable. Except as expressly set forth herein, we have not undertaken any independent investigation to determine the existence
424B5
8h4tidb1gah
1 Apr 24
Prospectus supplement for primary offering
10:30am
20-F/A
48toy0v72 1bv7pxgohd
26 Mar 24
Annual report (foreign) (amended)
4:57pm
20-F/A
EX-15.1
y1c7 nqtd5nv
26 Mar 24
Annual report (foreign) (amended)
4:57pm
S-8
EX-23.2
w95tjiav 2j17eby
29 Dec 23
Registration of securities for employees
4:20pm
S-8
rhnriw
29 Dec 23
Registration of securities for employees
4:20pm
F-3
fz48p2g0dym
29 Dec 23
Shelf registration (foreign)
4:15pm
F-3
EX-23.1
ok9mk4 12etl8zax7paz
29 Dec 23
Shelf registration (foreign)
4:15pm
6-K
yhkhnrtyzb24 4j
12 Dec 23
Current report (foreign)
7:07am
6-K
EX-99
yvbb9k9tgbuas4cc3
20 Nov 23
BioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate
7:03am
6-K
EX-99
juy7g8mp058tqit
20 Nov 23
BioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate
7:03am
6-K
EX-99
38dzie54usi
30 Aug 23
BioLineRx Reports Second Quarter 2023 Financial Results and Recent Corporate
7:15am
6-K
EX-99
pdadkszsa1n
30 Aug 23
BioLineRx Reports Second Quarter 2023 Financial Results and Recent Corporate
7:15am
6-K
EX-99
gk2xd
30 Aug 23
Current report (foreign)
6:45am